Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Egeberg, Alexander; Rosenø, Nana A.L.; Aagaard, David; Lørup, Erik Hillo; Nielsen, Mia‐Louise; Nymand, Lea K; Kristensen, Lars Erik; Thyssen, Jacob P.; Thomsen, Simon Francis; Cordtz, René; Loft, Nikolai; Skov, Lone; Bryld, Lars Erik; Rasmussen, Majken Kirkegaard; Højgaard, Pil; Kristensen, S. D.; Dreyer, Lene

doi:10.1016/j.semarthrit.2022.151979

Cited by 59 publications

(36 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is consistent with a previous BIOBADASER analysis (Pombo‐Suarez et al., 2021), and also with a Spanish study that evaluated a range of biological DMARDs and found that a higher percentage of SpA and PsA patients (51.6% and 59.7%) compared with RA patients (41.0%) continued with their first drug after a mean 3.8 years of follow‐up (Cañete et al., 2020). Our findings also align with those from a recent analysis from the DANBIO cohort on 17,903 series of treatments with biologics or targeted synthetic DMARDs which described higher drug survival for golimumab in axial SpA compared to all other therapies, and a tendency towards higher survival in PsA, but not in RA (Egeberg et al., 2022).…”

Section: Discussionsupporting

confidence: 91%

“…The current study did not compare golimumab retention rates with those of other TNFi drugs. However, multiple previous studies in a clinical practice setting suggest that golimumab retention rates are as good as, or better than, those seen with other TNFi drugs in patients with immune‐mediated rheumatic diseases (Dalén et al., 2016; Ebina et al., 2019; Egeberg et al., 2022; Kim et al., 2021; Svedbom, Storck et al., 2017).…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

Pombo‐Suárez

Seoane‐Mato

Dı́az-González

et al. 2022

Musculoskeletal Care

View full text Add to dashboard Cite

Aim:To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors.Methods: Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever started golimumab >6 months before the analysis for an approved indication (rheumatoid arthritis [RA], axial spondyloarthritis [SpA] or psoriatic arthritis [PsA]).Results: Among 885 patients (RA 267, axial SpA 370, PsA 248) receiving 944 cycles of golimumab, the retention rate of golimumab was 71.1% (95% confidence interval:This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 97%

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

Pombo‐Suárez

Seoane‐Mato

Dı́az-González

et al. 2022

Musculoskeletal Care

View full text Add to dashboard Cite

show abstract

“…Largest differences were seen for the rate of discontinuation citing adverse events, where the ranked (highest to lowest) order we observed was similar to that by overall drug survival in a contemporary cohort of Danish patients with RA. 13 It may in reality be difficult to assign a single cause for the choice to discontinue therapy (missing data can be substantial 14 ) and a lower rate of discontinuation citing safety should not be directly interpreted as a better drug safety profile. We saw the lowest rate on rituximab, consistent with previous reports that this drug has longer overall drug survival than other b/tsDMARDs, 14 15 despite a relatively higher rate of hospitalisation and serious infections.…”

Section: Discussionmentioning

confidence: 99%

“…61 (14) 59 (13) Female, % serious infections and more than tripled for herpes zoster among patients with RA on b/tsDMARDs. Infliximab and rituximab had about 30% higher rate of overall serious infections than etanercept, while the others had similar and non-significantly different rates.…”

Section: Incidence Rate By B/tsdmardmentioning

confidence: 99%

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

et al. 2023

View full text Add to dashboard Cite

ObjectiveLongitudinal clinical registry-infrastructures such as Anti-Rheumatic Therapies in Sweden (ARTIS) allow simultaneous comparison of the safety of individual immunomodulatory drugs used in clinical practice, with consistent definitions of treatment cohorts, follow-up and outcomes. Our objective was to assess and compare incidence rates of key safety outcomes for individual targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) in rheumatoid arthritis (RA), updating previous reports and including newer treatments including Janus Kinase inhibitors (JAKi).MethodsNationwide register-based cohort study including all patients with RA in Sweden registered as starting any b/tsDMARD 1 January 2010 through 31 December 2020, followed until 30 June 2021 (N=20 117). The incidence rates of selected outcomes, identified through national healthcare registers, were compared between individual b/tsDMARDs, adjusted for confounding by demographics, RA disease characteristics and comorbidity.ResultsThere were marked differences in treatment discontinuations due to adverse events (rates per 1000 person-years ranged from 18 on rituximab to 57 on tofacitinib), but few significant differences were observed for the serious adverse events under study. Neither cardiovascular events nor general serious infections were more frequent on baricitinib or tofacitinib versus bDMARDs, but JAKi were associated with higher rates of hospital-treated herpes zoster (HR vs etanercept, 3.82 (95% CI 2.05 to 7.09) and 4.00 (1.59 to 10.06)). Low number of events limited some comparisons, in particular for sarilumab and tofacitinib.ConclusionData from ARTIS supports that the b/tsDMARDs currently used to treat RA have acceptable and largely similar safety profiles, but differences exist in particular concerning tolerability and specific infection risks.

show abstract

“…Female sex, number of previous biologics, and depression have also been related to poorer survival of SEC in real world evidence studies [ 9 ]. Patients who start IXE retain the drug in a large percentage for at least 12 months according to most RCTs carried out to date [ 5 , 6 , 7 ], but long-term data regarding IXE survival in daily clinical practice are limited [ 14 , 15 ]. Unlike other studies with biologics [ 9 , 11 , 12 , 13 ], we did not detect significant alterations of IXE survival rate in relation to age, gender, smoking, duration of illness, or metabolic comorbidities (including obesity).…”

Section: Discussionmentioning

confidence: 99%

Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience

Braña

Pardo

Burger

et al. 2023

JCM

View full text Add to dashboard Cite

Background and objectives: Information on the performance of ixekizumab (IXE) in patients with psoriatic arthritis (PsA) in clinical practice is scarce. We aimed to analyze the retention rate and safety of IXE in patients with PsA in routine clinical practice. Methods: A retrospective longitudinal observational single-center study of all patients with PsA who had received at least one dose of IXE. Adverse events (AEs) and drug retention rate were the main study focus. Survival was analyzed using Kaplan–Meier curves and predictive factors using multivariate Cox regression analysis. The hazard ratio (HR) was used as a measure of the association. Results: Seventy-two patients were included (52 women and 20 men). Median disease duration was 5 years (IQR 3–9). More than 90% received ≥2 biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) prior to IXE. Ixekizumab showed a 1-year retention rate of 65% and a 2-year retention rate of 57%. Regarding discontinuation due to AEs, 0.18 AEs per person-year were identified. The number of previous biologics did not influence drug survival but prior use of methotrexate (HR 2.31 (95% CI 1.05–5.10), p < 0.05) and depression (HR 2.40 (95% CI 1.07–5.41), p < 0.05) increased the risk of IXE discontinuation. Conclusions: Ixekizumab showed a good retention rate in a PsA population mostly refractory to biologic and targeted synthetic DMARDs. Drug survival was consistently good regardless of age, gender, metabolic comorbidities, smoking status, or prior number of biologic therapies. This information may be of interest to better position this drug in the PsA treatment algorithms.

show abstract

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Cited by 59 publications

References 23 publications

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience

Contact Info

Product

Resources

About